Research programme: liposomal HIV vaccine - Xenetic Biosciences

Drug Profile

Research programme: liposomal HIV vaccine - Xenetic Biosciences

Latest Information Update: 27 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipoxen Technologies
  • Developer Xenetic Biosciences
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 27 Nov 2014 No development reported for HIV infections in USA (Parenteral)
  • 08 Sep 2011 Lipoxen is now called Xenetic Biosciences
  • 09 Apr 2011 Lipoxen and IAVI extend their collaboration on the development of the liposomal HIV vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top